486 completed, 188 unknown, 180 recruiting, 107 terminated. 321 Phase 2, 261 Not applicable, 189 Phase 1, 106 Phase 3, 16 Phase 4.
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 60 | 2028-07-31 | 2026-07-22 |
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-10-01 |
| Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) ATO-101™ - Bladder Cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 24 | 2027-01-01 | 2026-06-08 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-20 | 2026-09-21 |
| Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients Hyperthermic Intravesical Chemotherapy (HIVEC) - Non Muscle Invasive Bladder Cancer, Bladder Cancer | Not applicable | Not yet recruiting | AC.TA. S.r.l. | 50 | 2026-10-15 | 2026-05-06 |
| Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma | Not yet recruiting | University of Oklahoma | 2000 | 2026-10-01 | 2026-07-29 | |
| Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy Acupuncture, Exercise - Metastatic Bladder Cancer, Peripheral Neuropathy | Not applicable | Recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-03 | 2026-10-26 |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure Intravesical Instillation of Disitamab Vedotin Combined with Toripalimab - Bladder Cancer | Phase 1 | Not yet recruiting | Xiangya Hospital of Central South University | 20 | 2026-09-01 | 2026-08-25 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors CURTIS retrieval device - Bladder Cancer, Bladder Cancer TNM Staging Primary Tumor (T) T1 | Not applicable | Not yet recruiting | Ludwig-Maximilians - University of Munich | 75 | 2026-09-01 | 2026-08-17 |
| The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial FAPI PET/CT and liquid biopsy in patients eligible for radical cystectomy, FAPI PET/CT and liquid biopsy in patients eligible for conservative treatment - Bladder Cancer | Phase 2 | Not yet recruiting | Chiti Arturo | 262 | 2026-09-01 | 2025-12-02 |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
| Feasibility of HISA During TURBT for NMIBC HISA - Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Not applicable | Not yet recruiting | CAMC Health System | 40 | 2026-08-15 | 2026-09-14 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC Active Surveillance, Adjuvant Intravesical Chemotherapy - Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC) | Not applicable | Recruiting | Tianjin Medical University Second Hospital | 670 | 2026-08-10 | 2026-10-09 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
Showing 20 of 1119. Sign in to see all of them.
Urinary Bladder Neoplasms (1119) · Prostatic Neoplasms (111) · Carcinoma, Transitional Cell (110) · Ovarian Neoplasms (95) · Lung Neoplasms (90) · Breast Neoplasms (85) · Carcinoma, Non-Small-Cell Lung (84) · Colorectal Neoplasms (81) · Kidney Neoplasms (80) · Non-Muscle Invasive Bladder Neoplasms (80) · Pancreatic Neoplasms (79) · Stomach Neoplasms (76) · Neoplasms (69) · Esophageal Neoplasms (64) · Head and Neck Neoplasms (64)
Female Urogenital Diseases (1119) · Female Urogenital Diseases and Pregnancy Complications (1119) · Male Urogenital Diseases (1119) · Urogenital Diseases (1119) · Neoplasms by Site (1118) · Urologic Diseases (1110) · Urogenital Neoplasms (1109) · Urinary Bladder Diseases (1103) · Urologic Neoplasms (1101) · Neoplasms (1050) · Neoplasms by Histologic Type (326) · Neoplasms, Glandular and Epithelial (296) · Carcinoma (280) · Genital Diseases (191) · Digestive System Diseases (167)
Gemcitabine (100) · Cisplatin (77) · pembrolizumab (42) · Paclitaxel (32) · Cystectomy (29) · Mitomycin (27) · Carboplatin (26) · Docetaxel (25) · Radiotherapy (23) · BCG Vaccine (22) · atezolizumab (22) · Nivolumab (18) · Doxorubicin (17) · durvalumab (16) · Cystoscopy (14)
Memorial Sloan Kettering Cancer Center (44) · M.D. Anderson Cancer Center (21) · Mansoura University (20) · National Cancer Institute (NCI) (19) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (18) · UNC Lineberger Comprehensive Cancer Center (14) · University of Kansas Medical Center (14) · European Organisation for Research and Treatment of Cancer - EORTC (12) · SWOG Cancer Research Network (12) · Assiut University (9) · Dana-Farber Cancer Institute (9) · Merck Sharp & Dohme LLC (9) · Photocure (9) · The First Affiliated Hospital with Nanjing Medical University (9) · University Health Network, Toronto (9)
United States (525) · China (120) · United Kingdom (88) · Canada (83) · France (79) · Italy (72) · Spain (68) · Denmark (48) · Australia (44) · Netherlands (42) · Germany (41) · Belgium (36) · South Korea (36) · Egypt (33) · Poland (26)
Dean Bajorin, MD (7) · Ahmed Mosbah, MD (6) · Amr A Elsawy (6) · Dean F. Bajorin, MD (6) · Jian Huang, MD (6) · Andrea B Apolo, M.D. (4) · Eugene Lee, MD (4) · Ali Kaan Yildiz (3) · Arlene Siefker-Radtke, MD (3) · Armine Smith, MD (3)
PMID 38045238, PMID 38167321, PMID 16389183, PMID 11001674, PMID 17409436, PMID 17452976, PMID 19687335, PMID 20850152, PMID 22512481, PMID 22877502, PMID 23982601, PMID 24373477, PMID 25150172, PMID 25366678, PMID 25651787, PMID 26952546, PMID 27939400, PMID 28453896, PMID 29141603, PMID 29203268, PMID 29489427, PMID 29562804, PMID 33241650, PMID 33408185, PMID 33539743, PMID 37496366, PMID 39069239, PMID 41044356, PMID 41074972, PMID 10519404, PMID 11224527, PMID 11229684, PMID 11844814, PMID 11923603, PMID 12032861, PMID 12091876, PMID 12118019, PMID 12136861, PMID 12448661, PMID 12525530, PMID 12538684, PMID 12586807, PMID 12767086, PMID 12913696, PMID 1355007, PMID 14529770, PMID 14734003, PMID 15030777, PMID 15073851, PMID 15093567
U10CA032102 (10), 2017 (9), 2019 (7), 2023 (7), 2018 (5), P50CA091846 (5), 2014 (4), R01CA198887 (4), 2025 (3), 2015 (2), 2016 (2), P30CA016672 (2), P30CA138292 (2), U10CA031946 (2), 2005 (1)